Bioxytran, Inc. (BIXT) Research

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.

Market snapshot

Symbol
BIXT
Price
$0.03
Day change
-0.92%
Market cap
$3.4M
P/E ratio
-1.19x
52-week range
0.0262-0.1184
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BetterLife Pharma Inc. (BETRF)
  • BioVaxys Technology Corp. (BVAXF)
  • Burzynski Research Institute, Inc. (BZYR)
  • Mosaic ImmunoEngineering Inc. (CPMV)
  • Glow Lifetech Corp. (GLWLF)
  • Kane Biotech Inc. (KNBIF)
  • MYND Life Sciences Inc. (MYNDF)
  • NanoSphere Health Sciences Inc. (NSHSF)

Recent insider activity

  • Hoberman Alan M — A-Award (38588 shares) on 2025-11-14
  • Hoberman Alan M — A-Award (10417 shares) on 2025-08-12
  • Hoberman Alan M — P-Purchase (210000 shares) on 2025-11-18
  • MILANOVA RADKA — A-Award (38588 shares) on 2025-11-14
  • MILANOVA RADKA — A-Award (10417 shares) on 2025-08-12

Open Bioxytran, Inc. (BIXT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.